Search results
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore...
Morningstar· 7 days ago“Bezisterim” has been approved as the non-proprietary name for NE3107Data shows how bezisterim may be restoring homeostasis via specific ...
Deterra Honored As Silver Stevie Award Winner in 2024 American Business Awards
Quincy Herald-Whig· 1 day agoVerde Environmental Technologies, Inc.'s Deterra® Drug Deactivation and Disposal System was named a winner of a Silver Stevie® Award in the category "Products in the Area ...
Barinthus Bio names Leon Hooftman as new CMO By Investing.com
Investing.com· 7 hours agoDr. Hooftman, who holds an MD from Utrecht State University and has specialist training from...
AptarGroup, Inc. (NYSE:ATR) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 day agoAptarGroup, Inc. (NYSE:ATR) Q1 2024 Earnings Call Transcript April 26, 2024 AptarGroup, Inc. isn’t...
Biodexa shares rally 126% on rapamycin licensing deal (NASDAQ:BDRX)
Seeking Alpha· 5 days agoBiodexa (BDRX) stock soared 126% Friday after the company announced an exclusive icensing deal to...
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer - Barinthus...
Benzinga· 14 hours agoBarinthus Biotherapeutics plc BRNS, formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system ...
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
Digital Journal· 5 days ago...A Unique AI Trading Platform for Canadian Citizens Almaden Files Form 20-F Documentation International Cobalt Announces Name Change Jelly Crash Announces Solana’s First Casino Patagonia Gold 2023 Financial Results More from Digital Journal Let’s...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 7 days agoPhase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for oral abstract presentation